Your shopping cart is currently empty

D4-abiraterone is the active metabolite of abiraterone produced by 3β-HSD and is further metabolised by SRD5A.Δ4-Abiraterone is an inhibitor of CYP17A1, 3β-HSD and SRD5A, and an antagonist of the androgen receptor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | - | In Stock | |
| 5 mg | $89 | - | In Stock | |
| 10 mg | $163 | - | In Stock | |
| 25 mg | $363 | - | In Stock | |
| 50 mg | $538 | - | In Stock | |
| 100 mg | $766 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | - | In Stock |
| Description | D4-abiraterone is the active metabolite of abiraterone produced by 3β-HSD and is further metabolised by SRD5A.Δ4-Abiraterone is an inhibitor of CYP17A1, 3β-HSD and SRD5A, and an antagonist of the androgen receptor. |
| Targets&IC50 | Androgen receptor:5.3-7.9 nM |
| In vitro | D4-abiraterone (10 μM) nearly fully blocks AD conversion to 5α-androgens. D4-abiraterone binds AR more strongly (IC₅₀ = 5.3-7.9 nM) than abiraterone (IC₅₀ = 418-500+ nM), and more effectively suppresses AR target genes like PSA[1]. |
| In vivo | In LNCaP and VCaP mouse tumors, D4-abiraterone was 10× stronger than abiraterone. At 0.1 μM, D4-abiraterone matched 1 μM abiraterone in blocking AD formation and delayed tumor growth within 48 h[1]. |
| Synonyms | Δ4-Abiraterone, Delta4-Abiraterone, CB-7627, CB7627, Abiraterone D4A metabolite |
| Molecular Weight | 347.49 |
| Formula | C24H29NO |
| Cas No. | 154229-21-7 |
| Smiles | C[C@@]12[C@]([C@]3([C@@]([C@]4(C)C(CC3)=CC(=O)CC4)(CC1)[H])[H])(CC=C2C=5C=CC=NC5)[H] |
| Relative Density. | 1.14 g/cm3 (Predicted) |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (115.11 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (2.88 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.